Lavipharm (Greece) Insiders
| LAVI Stock | EUR 0.71 0.01 1.39% |
Lavipharm employs about 5 people. The company is managed by 9 executives with a total tenure of roughly 12 years, averaging almost 1.0 years of service per executive, having 0.56 employees per reported executive. Breaking down Lavipharm's management performance can provide insight into the firm performance.
| Katerina Fragioudakis Insider Head Chairman |
| Vassilis Baloumis Insider Group CFO |
Lavipharm |
Lavipharm Management Team Effectiveness
The company has return on total asset (ROA) of 0.0403 % which means that it generated a profit of $0.0403 on every $100 spent on assets. This is way below average. Lavipharm's management efficiency ratios could be used to measure how well Lavipharm manages its routine affairs as well as how well it operates its assets and liabilities.Lavipharm Workforce Comparison
Lavipharm SA is rated fifth overall in number of employees category among its peers. The total workforce of Drug Manufacturers - Major industry is now estimated at about 13,892. Lavipharm adds roughly 5.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers - Major industry.
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08. Lavipharm SA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Lavipharm SA Price Series Summation is a cross summation of Lavipharm price series and its benchmark/peer.
Lavipharm Notable Stakeholders
A Lavipharm stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lavipharm often face trade-offs trying to please all of them. Lavipharm's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lavipharm's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Katerina Fragioudakis | Head Chairman | Profile | |
| Vassilis Baloumis | Group CFO | Profile | |
| Panagiotis Giannouleas | COO Mang | Profile | |
| Spyridon Fotinos | Chief Officer | Profile | |
| Liana Dimitrakopoulou | Investor Officer | Profile | |
| Lucia Tweezers | VP Board | Profile | |
| Panagiotis Pavlou | Group Director | Profile | |
| Eleana Nikolopoulou | Group Sec | Profile | |
| Telemaque Lavidas | Ex Director | Profile |
About Lavipharm Management Performance
The success or failure of an entity such as Lavipharm SA often depends on how effective the management is. Lavipharm management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lavipharm management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lavipharm management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange.
Please note, the imprecision that can be found in Lavipharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lavipharm SA. Check Lavipharm's Beneish M Score to see the likelihood of Lavipharm's management manipulating its earnings.
Lavipharm Workforce Analysis
Traditionally, organizations such as Lavipharm use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lavipharm within its industry.Lavipharm Manpower Efficiency
Return on Lavipharm Manpower
| Revenue Per Employee | 8.3M | |
| Revenue Per Executive | 4.6M | |
| Net Income Per Employee | 344.6K | |
| Net Income Per Executive | 191.4K |
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.